Analyst Price Targets — CTMX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 4, 2026 10:46 am | — | Barclays | $10.00 | $6.07 | TheFly | CytomX Therapeutics price target raised to $10 from $8 at Barclays |
| January 20, 2026 11:48 am | — | Piper Sandler | $10.00 | $5.39 | TheFly | CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler |
| January 20, 2026 11:48 am | Michael Schmidt | Guggenheim | $10.00 | $5.39 | TheFly | CytomX Therapeutics initiated with a Buy at Guggenheim |
| January 20, 2026 11:37 am | Etzer Darout | Barclays | $8.00 | $5.39 | TheFly | CytomX Therapeutics price target raised to $8 from $6 at Barclays |
| October 21, 2025 9:19 am | Etzer Darout | Barclays | $6.00 | $3.74 | TheFly | CytomX Therapeutics price target raised to $6 from $3.50 at Barclays |
| September 16, 2025 8:46 pm | Etzer Darout | Barclays | $3.50 | $1.96 | TheFly | CytomX Therapeutics assumed with an Overweight at Barclays |
| July 31, 2025 10:03 am | Matthew Biegler | Oppenheimer | $7.00 | $2.32 | TheFly | CytomX Therapeutics initiated with an Outperform at Oppenheimer |
| November 8, 2024 2:13 pm | Etzer Darout | BMO Capital | $3.68 | $1.09 | StreetInsider | CytomX Therapeutics (CTMX) PT Raised to $3.68 at BMO Capital |
| November 8, 2024 1:45 pm | Joseph Catanzaro | Piper Sandler | $3.25 | $1.09 | StreetInsider | CytomX Therapeutics (CTMX) PT Lowered to $3.25 at Piper Sandler |
| August 9, 2024 7:58 am | Etzer Darout | BMO Capital | $3.56 | $1.18 | StreetInsider | CytomX Therapeutics (CTMX) PT Lowered to $3.56 at BMO Capital |
Latest News for CTMX
CytomX Therapeutics (NASDAQ: CTMX) Chief Financial Officer Chris Ogden outlined the company's current priorities and upcoming catalysts during a fireside chat moderated by Guggenheim senior biotech analyst Michael Schmidt. Ogden said CytomX has spent more than 15 years developing its "masked biologics" technology, which is designed to keep an antibody or other biologic therapeutics inactive in
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferences in February.
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of…
EMERYVILLE, Calif.--(BUSINESS WIRE)--Wareham Development today confirmed a full floor lease has been signed with CytomX Therapeutics at 5959 Horton Street (EmeryStation West).
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) has been given an average rating of "Moderate Buy" by the seven brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CTMX.
U.S. House Trading
No House trades found for CTMX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.